Sales & Marketing News | pharmaphorum

News

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S

News

Pfizer launches cost-cutting drive as COVID sales fall

Pfizer has said it will shed staff and cut its operating costs by around $3.5 billion, as it faces a shortfall in COVID-19 vaccine and treatment sales, with revenues now e

News

Eversana acquires pharmaphorum owner Healthware Group

Eversana has acquired pharmaphorum parent Healthware Group in a move that elevates the longstanding partnership between the companies, expands their geographic reach, and

News

PM Society Awards 2024 opens for entries

The prestigious PM Society Awards 2024 has officially opened for entries, marking the 38th year

News

Sanofi spin-off EuroAPI slumps as revenues falter

Shares in EuroAPI, the active pharmaceutical ingredients (API) business spun out of Sanofi last year, have fallen sharply on the back of a sharp slowdown in sales.

News

Bayer backs cell therapy ambition with $250m US facility

Bayer is backing up its move into the cell therapy category led by subsidiary BlueRock Therapeutics with a $250 million investment in a new manufacturing facility in Berke

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

Pfizer launches cost-cutting drive as COVID sales fall

Eversana acquires pharmaphorum owner Healthware Group

PM Society Awards 2024 opens for entries

Sanofi spin-off EuroAPI slumps as revenues falter

Bayer backs cell therapy ambition with $250m US facility

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks